Establishment Labs (NASDAQ:ESTA) Shares Down 7.4% - Should You Sell?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) traded down 7.4% during trading on Thursday . The stock traded as low as $35.51 and last traded at $35.23. 176,473 shares were traded during trading, a decline of 58% from the average session volume of 416,768 shares. The stock had previously closed at $38.05.

Analyst Upgrades and Downgrades

Separately, Stephens reissued an "overweight" rating and issued a $52.00 price target on shares of Establishment Labs in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $57.40.

Establishment Labs Trading Up 6.0 %

The firm has a market cap of $1.13 billion, a PE ratio of -15.22 and a beta of 0.95. The firm has a fifty day simple moving average of $36.43 and a two-hundred day simple moving average of $41.02. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.34). The company had revenue of $44.51 million during the quarter, compared to analysts' expectations of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Equities analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Establishment Labs

A number of institutional investors have recently added to or reduced their stakes in ESTA. Toronto Dominion Bank bought a new position in shares of Establishment Labs in the fourth quarter worth approximately $24,879,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Establishment Labs by 15.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock worth $2,196,000 after buying an additional 6,307 shares during the last quarter. Union Square Park Capital Management LLC increased its position in Establishment Labs by 47.0% during the fourth quarter. Union Square Park Capital Management LLC now owns 160,000 shares of the company's stock valued at $7,371,000 after acquiring an additional 51,192 shares during the last quarter. Vestal Point Capital LP grew its position in Establishment Labs by 650.0% during the fourth quarter. Vestal Point Capital LP now owns 300,000 shares of the company's stock valued at $13,821,000 after buying an additional 260,000 shares during the period. Finally, Stonepine Capital Management LLC increased its stake in shares of Establishment Labs by 6.7% in the 4th quarter. Stonepine Capital Management LLC now owns 80,002 shares of the company's stock worth $3,686,000 after purchasing an additional 5,002 shares in the last quarter. Institutional investors own 72.91% of the company's stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.